HDAC Inhibition Modulates Cardiac PPARs and Fatty Acid Metabolism in Diabetic Cardiomyopathy

Peroxisome proliferator-activated receptors (PPARs) regulate cardiac glucose and lipid homeostasis. Histone deacetylase (HDAC) inhibitor has anti-inflammatory effects which may play a key role in modulating PPARs and fatty acid metabolism. The aim of this study was to investigate whether HDAC inhibitor, MPT0E014, can modulate myocardial PPARs, inflammation, and fatty acid metabolism in diabetes mellitus (DM) cardiomyopathy. Electrocardiography, echocardiography, and western blotting were used to evaluate the electrophysiological activity, cardiac structure, fatty acid metabolism, inflammation, and PPAR isoform expressions in the control and streptozotocin-nicotinamide-induced DM rats with or without MPT0E014. Compared to control, DM and MPT0E014-treated DM rats had elevated blood glucose levels and lower body weights. However, MPT0E014-treated DM and control rats had smaller left ventricular end-diastolic diameter and shorter QT interval than DM rats. The control and MPT0E014-treated DM rats had greater cardiac PPAR-α and PPAR-δ protein expressions, but less cardiac PPAR-γ than DM rats. Moreover, control and MPT0E014-treated DM rats had lower concentrations of 5′ adenosine monophosphate-activated protein kinase 2α, PPAR-γ coactivator 1α, phosphorylated acetyl CoA carboxylase, cluster of differentiation 36, diacylglycerol acyltransferase 1 (DGAT1), DGAT2, tumor necrosis factor-α, and interleukin-6 protein than DM rats. HDAC inhibition significantly attenuated DM cardiomyopathy through modulation of cardiac PPARS, fatty acid metabolism, and proinflammatory cytokines.

[1]  P. McNamara,et al.  Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study , 1974, Diabetes.

[2]  G. Lopaschuk,et al.  Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats. , 1989, Biochimica et biophysica acta.

[3]  J. Chatham,et al.  Relationship between cardiac function and substrate oxidation in hearts of diabetic rats. , 1997, The American journal of physiology.

[4]  M. Novelli,et al.  Experimental NIDDM: Development of a New Model in Adult Rats Administered Streptozotocin and Nicotinamide , 1998, Diabetes.

[5]  P. Douglas,et al.  Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with doppler echocardiography and contribution of the nitric oxide pathway. , 1999, Journal of the American College of Cardiology.

[6]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[7]  R. Marfella,et al.  High glucose induces ventricular instability and increases vasomotor tone in rats , 2001, Diabetologia.

[8]  Yanhong Shi,et al.  The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Doron Aronson,et al.  How hyperglycemia promotes atherosclerosis: molecular mechanisms , 2002, Cardiovascular diabetology.

[10]  Xianlin Han,et al.  The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. , 2002, The Journal of clinical investigation.

[11]  A. Bonen,et al.  Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. , 2003, Diabetes.

[12]  G. Rutter,et al.  Roles of 5'-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. , 2003, The Biochemical journal.

[13]  D. Hardie.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0982 Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status , 2022 .

[14]  T. Giles.  The patient with diabetes mellitus and heart failure: at-risk issues. , 2003, The American journal of medicine.

[15]  S. Pillarisetti,et al.  Role of oxidative stress and inflammation in the origin of Type 2 diabetes – a paradigm shift , 2004, Expert opinion on therapeutic targets.

[16]  Rama Natarajan,et al.  In Vivo Chromatin Remodeling Events Leading to Inflammatory Gene Transcription under Diabetic Conditions* , 2004, Journal of Biological Chemistry.

[17]  Robert V Farese,et al.  Lipopenia and Skin Barrier Abnormalities in DGAT2-deficient Mice* , 2004, Journal of Biological Chemistry.

[18]  R. Cooksey,et al.  Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. , 2005, Endocrinology.

[19]  H. Lamb,et al.  Diabetic cardiomyopathy in uncomplicated type 2 diabetes is associated with the metabolic syndrome and systemic inflammation , 2005, Diabetologia.

[20]  J. McGill,et al.  Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. , 2006, Journal of the American College of Cardiology.

[21]  Sanjoy Ghosh,et al.  AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes. , 2007, Journal of molecular and cellular cardiology.

[22]  B. Finck,et al.  The PPAR regulatory system in cardiac physiology and disease. , 2007, Cardiovascular research.

[23]  J. Plutzky,et al.  Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. , 2007, Circulation.

[24]  B. Spiegelman,et al.  AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α , 2007, Proceedings of the National Academy of Sciences.

[25]  J. McNeill,et al.  Cardiac expression of adiponectin and its receptors in streptozotocin-induced diabetic rats. , 2007, Metabolism: clinical and experimental.

[26]  M. Drazner,et al.  Cardiomyopathy in Type 2 Diabetes , 2008, Herz Kardiovaskuläre Erkrankungen.

[27]  E. Olson,et al.  Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. , 2008, The Journal of clinical investigation.

[28]  Robert V Farese,et al.  Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. , 2008, Journal of lipid research.

[29]  Ting-I Lee,et al.  Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator‐activated receptors , 2009, European journal of clinical investigation.

[30]  Yuguang Shi,et al.  Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. , 2009, American journal of physiology. Endocrinology and metabolism.

[31]  B. Ganesan,et al.  Tissue-Specific Remodeling of the Mitochondrial Proteome in Type 1 Diabetic Akita Mice , 2009, Diabetes.

[32]  S. Kliewer,et al.  FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response , 2009, Proceedings of the National Academy of Sciences.

[33]  M. Sweet,et al.  Histone deacetylase inhibitors in inflammatory disease. , 2009, Current topics in medicinal chemistry.

[34]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[35]  Nan-Hung Pan,et al.  Oxidative stress and inflammation modulate peroxisome proliferator‐activated receptors with regional discrepancy in diabetic heart , 2010, European journal of clinical investigation.

[36]  P. Munson,et al.  Caloric restriction in leptin deficiency does not correct myocardial steatosis: failure to normalize PPARα/PGC1α and thermogenic glycerolipid/fatty acid cycling , 2011 .

[37]  P. Munson,et al.  Caloric restriction in leptin deficiency does not correct myocardial steatosis: failure to normalize PPAR{alpha}/PGC1{alpha} and thermogenic glycerolipid/fatty acid cycling. , 2011, Physiological genomics.

[38]  B. Stratmann,et al.  Heart in Diabetes: Not Only a Macrovascular Disease , 2011, Diabetes Care.

[39]  Nan-Hung Pan,et al.  Cardiac peroxisome-proliferator-activated receptor expression in hypertension co-existing with diabetes. , 2011, Clinical science.

[40]  N. Billestrup,et al.  Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus , 2011, Molecular medicine.

[41]  Shih-Ann Chen,et al.  Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. , 2013, International journal of cardiology.

[42]  Dhiren P. Shah,et al.  ON OXIDATIVE STRESS AND DIABETIC COMPLICATIONS , 2013 .

[43]  Antonello Mai,et al.  Inhibition of Class I Histone Deacetylases Unveils a Mitochondrial Signature and Enhances Oxidative Metabolism in Skeletal Muscle and Adipose Tissue , 2013, Diabetes.

[44]  Yi‐Jen Chen,et al.  Rosiglitazone induces arrhythmogenesis in diabetic hypertensive rats with calcium handling alteration. , 2013, International journal of cardiology.

[45]  E. Abel,et al.  Molecular mechanisms of diabetic cardiomyopathy , 2014, Diabetologia.

[46]  Wen-Chin Tsai,et al.  Cardiac metabolism, inflammation, and peroxisome proliferator-activated receptors modulated by 1,25-dihydroxyvitamin D3 in diabetic rats. , 2014, International journal of cardiology.

[47]  Zhanjun Jia,et al.  PPARs and Metabolic Syndrome , 2014, PPAR research.

[48]  S. Zhuang,et al.  Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice , 2015, Cardiovascular Diabetology.

[49]  E. Lewandowski,et al.  Impaired cytosolic NADH shuttling and elevated UCP3 contribute to inefficient citric acid cycle flux support of postischemic cardiac work in diabetic hearts. , 2015, Journal of molecular and cellular cardiology.

[50]  Shih-Ann Chen,et al.  Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure , 2015, Pharmacology.

[51]  J. Egido,et al.  Targeting metabolic disturbance in the diabetic heart , 2015, Cardiovascular Diabetology.

[52]  Shaodong Guo,et al.  Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function. , 2016, Circulation research.

[53]  M. Khullar,et al.  Emerging Evidence of Epigenetic Modifications in Vascular Complication of Diabetes , 2017, Front. Endocrinol..